This additional funding will allow Selux to continue implementing its microbiology roadmap and commercialize its Next Generation 'Phenotyping' (NGP) platform for rapid antimicrobial susceptibility testing.
The contract covers the T2Dx instrument as well as the T2Bacteria and T2Candida panels, which detect sepsis-causing bacterial and fungal pathogens directly from whole blood.
Gradientech’s QuickMIC is a precision tool for ultrarapid antibiotic susceptibility testing.
Capable of processing more than 200 culture plates at a time, the instrument responds to the growing demand of busy microbiology laboratories and the fast-growing automated pathology market.
The cost-effective test detects MUG, PYR, and Indole production on a single paper disc in as little as fifteen15 minutes.
A Medical University of South Carolina study found that use of a mechanical initial specimen diversion device and staff education led to a nearly four-fold decrease in contaminated blood cultures that was sustained over 20 months.
Series C funding will finance further development and CE marking of the company’s first molecular point-of-care platform based on pulse-controlled amplification technology.